Insight Molecular Diagnostics Inc.
IMDXCIK 0001642380 · In Vitro & In Vivo Diagnostic Substances · Nasdaq
- OncoCyte Corp (until 2025-06-17)
- Oncocyte Corp (until 2025-06-17)
Revenue (TTM)
$2.95M
+115.6% YoY
Q1 May 2026
Net Income (TTM)
−$31.56M
+17.2% YoY
Q1 May 2026
EPS Diluted (TTM)
−$1.02
+64.6% YoY
Q1 May 2026
Gross Margin
62.0%
Q1 May 2026
Operating Margin
-1,088.9%
Q1 May 2026
Net Margin
-1,070.5%
Q1 May 2026
Free Cash Flow (TTM)
−$28.11M
Q1 May 2026
Cash
$28.2M
Q1 May 2026
Total Debt
$1.87M
Q1 May 2026
Shares Outstanding
32.29M sh
Q1 May 2026
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
Balance Sheet
Cash vs Debt
Latest news
All news →-
Low Neutral
Insight Molecular (IMDX) Increases Stock Option Pool by 1.75M Shares
The diagnostic company seeks shareholder approval to expand its employee compensation plan.